Nsabp Foundation Inc. company information, Employees & Contact Information

Omitting Regional Nodal Irradiation after Response to Neoadjuvant Chemotherapy The New England Journal of Medicine

RNI Omission in ypN0 Breast Cancer-NRG B‑51/RTOG 1304 trial Oncodaily

NRG Oncology/NSABP B-47 menstrual history study: impact of adjuvant chemotherapy with and without trastuzumab Nature

Toxicity Index, Patient-Reported Outcomes, and Early Discontinuation of Endocrine Therapy for Breast Cancer Risk Reduction in NRG Oncology/NSABP B-35 ASCO Publications

NSABP FB-10: a phase Ib/II trial evaluating ado-trastuzumab emtansine (T-DM1) with neratinib in women with metastatic HER2-positive breast cancer Breast Cancer Research

National Accreditation Program for Breast Centers (NAPBC) The American College of Surgeons

NSABP Announces Centers Selected for the Study of Tamoxifen and Raloxifene(STAR) Fred Hutchinson Cancer Center

Neoadjuvant plus adjuvant bevacizumab in early breast cancer (NSABP B-40 [NRG Oncology]): secondary outcomes of a phase 3, randomised controlled trial The Lancet

NSABP B-51: Loco-Regional Irradiation in Patients Who Become Node Negative After Neoadjuvant Chemotherapy Targeted Oncology

A Multigene Assay to Predict Recurrence of Tamoxifen-Treated, Node-Negative Breast Cancer The New England Journal of Medicine

Tumour sidedness and intrinsic subtypes in patients with stage II/III colon cancer: analysis of NSABP C-07 (NRG Oncology) Nature

The 5-Year Paradigm in DCIS of the Breast: Unexpected Lessons From the NSABP B-43 Trial ASCO Publications

Paolo Tarantino: Thanks to NSABP-B51, Countless Patients Will Be Spared the Toxicity of Nodal Irradiation Oncodaily

Twenty-Year Follow-up of a Randomized Trial Comparing Total Mastectomy, Lumpectomy, and Lumpectomy plus Irradiation for the Treatment of Invasive Breast Cancer The New England Journal of Medicine

Twenty-Five-Year Follow-up of a Randomized Trial Comparing Radical Mastectomy, Total Mastectomy, and Total Mastectomy Followed by Irradiation The New England Journal of Medicine

Clinical and Genomic Risk to Guide the Use of Adjuvant Therapy for Breast Cancer The New England Journal of Medicine

Trastuzumab plus Adjuvant Chemotherapy for Operable HER2-Positive Breast Cancer The New England Journal of Medicine

Bevacizumab Added to Neoadjuvant Chemotherapy for Breast Cancer The New England Journal of Medicine

Longer Therapy, Iatrogenic Amenorrhea, and Survival in Early Breast Cancer The New England Journal of Medicine

Anastrozole versus tamoxifen in postmenopausal women with ductal carcinoma in situ undergoing lumpectomy plus radiotherapy (NSABP B-35): a randomised, double-blind, phase 3 clinical trial The Lancet

Duration of Adjuvant Chemotherapy for Stage III Colon Cancer The New England Journal of Medicine

Toxicity Index, patient-reported outcomes, and persistence of breast cancer chemotherapy-associated side effects in NRG Oncology/NSABP B-30 Nature

Priya Rastogi named CEO of NSABP Foundation The Cancer Letter

Survival with Trastuzumab Emtansine in Residual HER2-Positive Breast Cancer The New England Journal of Medicine

Pioneering Breast Surgeon and NSABP Chair, Bernard Fisher, MD, Dies at 101 The ASCO Post

New Analysis of NSABP Randomized B-20 Study Confirms Patients with Oncotype DX Breast Recurrence Score® Results Greater Than 25 Have Life-saving Benefit from Chemotherapy, Reinforcing the Conclusions of the Landmark TAILORx Study PR Newswire

SABCS 2023: Some Patients May Safely Skip Radiation American Association for Cancer Research (AACR)

Romond Elected to NSABP Board UKNow

Neoadjuvant plus adjuvant bevacizumab in early breast cancer (NSABP B-40 [NRG Oncology]): secondary outcomes of a phase 3, randomised controlled trial The Lancet

21-Gene assay as predictor of chemotherapy benefit in HER2-negative breast cancer | npj Breast Cancer Nature

Atypical Hyperplasia of the Breast — Risk Assessment and Management Options The New England Journal of Medicine

Effect of Occult Metastases on Survival in Node-Negative Breast Cancer The New England Journal of Medicine

Reanalysis and Results after 12 Years of Follow-up in a Randomized Clinical Trial Comparing Total Mastectomy with Lumpectomy with or without Irradiation in the Treatment of Breast Cancer The New England Journal of Medicine

Kaiser Permanente Research: Study of Early Stage Breast Cancer Patients Identifies Women at Low Risk of Breast Cancer Mortality Kaiser Permanente Division of Research

A Randomized Clinical Trial Evaluating Tamoxifen in the Treatment of Patients with Node-Negative Breast Cancer Who Have Estrogen-Receptor–Positive Tumors The New England Journal of Medicine